Gerade mal in das mittlere Drittel des Dax schafft es heute die Aktie von der Merck KGaA mit einer Seitwärtsbewegung von ...

Bearish flow noted in Merck (MRK) with 10,338 puts trading, or 1.1x expected. Most active are Jan-25 110 puts and Jan-25 115 puts, with total ...

Merck, a leading science and technology company, has signed a definitive agreement with the intention to acquire HUB Organoids Holding B.V. (HUB). Organoids are cell culture models that ...

Am letzten Handelstag des durchweg starken Börsenjahres liegt der QIX Deutschland am Montag mit 0,5 % im Minus bei 15.470 ...

Mit einer Seitwärtsbewegung von -0,04 Prozent reicht es bei der Aktie der Merck KGaA für eine Mittelposition im Dax.

Merck just licensed a weight-loss drug candidate. There's reason to believe that the candidate could have a big edge. But, success is not guaranteed, and the program will take years to develop ...

Organische Bauelemente sind nicht zuletzt durch moderne Fernseher mit organischen Leuchtdioden (OLEDs) in aller Munde. Doch ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...